相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。FDA Approval Summary: Idecabtagene Vicleucel for Relapsed or Refractory Multiple Myeloma
Poornima Sharma et al.
CLINICAL CANCER RESEARCH (2022)
Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies
Adam D. Cohen et al.
BLOOD CANCER JOURNAL (2022)
CAR T cell therapies for patients with multiple myeloma
Lekha Mikkilineni et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
Sustainable Efficacy and Safety Results from Lummicar Study 1: A Phase 1/2 Study of Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT053) in Chinese Subjects with Relapsed and/or Refractory Multiple Myeloma
Wenming Chen et al.
BLOOD (2021)
Universal Updated Phase 1 Data Validates the Feasibility of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma
Sham Mailankody et al.
BLOOD (2021)
Efficacy and Safety of Ciltacabtagene Autoleucel (Cilta-cel), a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Lenalidomide-Refractory Patients with Progressive Multiple Myeloma after 1-3 Prior Lines of Therapy: Updated Results from CARTITUDE-2
Yael C. Cohen et al.
BLOOD (2021)
Updated Clinical and Correlative Results from the Phase I CRB402 Study of the BCMA-Targeted CAR T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma
Noopur S. Raje et al.
BLOOD (2021)
Baseline Correlates of Complete Response to Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy in Patients with Relapsed and Refractory Multiple Myeloma: Subanalysis of the KarMMa Trial
Nina Shah et al.
BLOOD (2021)
Updated Results from CARTITUDE-1: Phase 1b/2Study of Ciltacabtagene Autoleucel, a B-Cell Maturation AntigenDirected Chimeric Antigen Receptor T Cell Therapy, in Patients With Relapsed/Refractory Multiple Myeloma
Thomas Martin et al.
BLOOD (2021)
KarMMa-7, a Phase 1/2, Dose-Finding and Dose-Expansion Study of Combination Therapies with Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM)
Noopur S. Raje et al.
BLOOD (2021)
CARTITUDE-2: Efficacy and Safety of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T-Cell Therapy, in Patients with Multiple Myeloma and Early Relapse after Initial Therapy
Niels W. C. J. Van de Donk et al.
BLOOD (2021)
Phase 1/2 Study of Nexi-002 Autologous MultiAntigen-Specific CD8+T Cells for the Treatment of Relapsed or Refractory Multiple Myeloma
Robert D. Knight et al.
BLOOD (2021)
Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy
Oliver Van Oekelen et al.
NATURE MEDICINE (2021)
T-Cell Therapy for Lymphoma Using Nonengineered Multiantigen-Targeted T Cells Is Safe and Produces Durable Clinical Effects
Spyridoula Vasileiou et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
Nikhil C. Munshi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in relapsed and refractory multiple myeloma: Updated KarMMa results.
Larry D. Anderson et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Ciltacabtagene autoleucel, a B-cell maturation antigendirected chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
Jesus G. Berdeja et al.
LANCET (2021)
B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches
Nina Shah et al.
LEUKEMIA (2020)
'Off-the-shelf' allogeneic CAR T cells: development and challenges
S. Depil et al.
NATURE REVIEWS DRUG DISCOVERY (2020)
CRISPR-engineered T cells in patients with refractory cancer
Edward A. Stadtmauer et al.
SCIENCE (2020)
Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed/refractory multiple myeloma (RRMM): update of the phase 1/2 EVOLVE study (NCT03430011).
Sham Mailankody et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Deregulation of Adaptive T Cell Immunity in Multiple Myeloma: Insights Into Mechanisms and Therapeutic Opportunities
Noemie Leblay et al.
FRONTIERS IN ONCOLOGY (2020)
CAR T-Cells in Multiple Myeloma: State of the Art and Future Directions
Luis Gerardo Rodriguez-Lobato et al.
FRONTIERS IN ONCOLOGY (2020)
The safety and clinical effects of administering a multiantigen-targeted T cell therapy to patients with multiple myeloma
Premal D. Lulla et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events
Marcela Maus et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Association of Baseline and Postinfusion Biomarkers with Safety and Efficacy Endpoints in Patients Treated with Orvacabtagene Autoleucel (orva-cel; JCARH125) in the Phase 1/2 Evolve Study (NCT03430011)
Julia Piasecki et al.
BLOOD (2020)
KarMMa-4: Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T-Cell Therapy, in High-Risk Newly Diagnosed Multiple Myeloma
Saad Z. Usmani et al.
BLOOD (2020)
Orvacabtagene Autoleucel (orva-cel; JCARH125): A Fully Human BCMA-Targeted Second-Generation CAR T Cell Product Characterized By a Predominant Central Memory Phenotype with High in Vitro and In Vivo Proliferative Potential and Sustained In Vivo Persistence
Lucrezia Colonna et al.
BLOOD (2020)
KarMMa-3: A Phase 3 Study of Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy Vs Standard Regimens in Relapsed and Refractory Multiple Myeloma
Michel Delforge et al.
BLOOD (2020)
Two-Year Follow-up of Investigator-Initiated Phase 1 Trials of the Safety and Efficacy of Fully Human Anti-Bcma CAR T Cells (CT053) in Relapsed/Refractory Multiple Myeloma
Siguo Hao et al.
BLOOD (2020)
Results from Lummicar-2: A Phase 1b/2 Study of Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT053) in Patients with Relapsed and/or Refractory Multiple Myeloma
Shaji K. Kumar et al.
BLOOD (2020)
Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy, in Patients with Relapsed and Refractory Multiple Myeloma: Updated Results from Phase 1 CRB-401 Study
Yi Lin et al.
BLOOD (2020)
Actors on the Scene: Immune Cells in the Myeloma Niche
Patrizia Leone et al.
FRONTIERS IN ONCOLOGY (2020)
Universal: An Allogeneic First-in-Human Study of the Anti-Bcma ALLO-715 and the Anti-CD52 ALLO-647 in Relapsed/Refractory Multiple Myeloma
Sham Mailankody et al.
BLOOD (2020)
Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells
Philipp Karschnia et al.
BLOOD (2019)
B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma
Adam D. Cohen et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
Noopur Raje et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
leExploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma
Jie Xu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Immunotherapy of Relapsed and Refractory Solid Tumors With Ex Vivo Expanded Multi-Tumor Associated Antigen Specific Cytotoxic T Lymphocytes: A Phase I Study
Amy B. Hont et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Orthotopic replacement of T-cell receptor α- and β-chains with preservation of near-physiological T-cell function
Kilian Schober et al.
NATURE BIOMEDICAL ENGINEERING (2019)
Phase 1 Trial of the Safety and Efficacy of Fully Human Anti-Bcma CAR T Cells in Relapsed/Refractory Multiple Myeloma
Jin Jie et al.
BLOOD (2019)
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
Daniel W. Lee et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
A Pilot Trial of the Combination of Transgenic NY-ESO-1-reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination with or without Ipilimumab
Theodore S. Nowicki et al.
CLINICAL CANCER RESEARCH (2019)
Results from CARTITUDE-1: A Phase 1b/2 Study of JNJ-4528, a CAR-T Cell Therapy Directed Against B-Cell Maturation Antigen (BCMA), in Patients with Relapsed and/or Refractory Multiple Myeloma (R/R MM)
Deepu Madduri et al.
BLOOD (2019)
Long-Term Follow-up of a Phase 1, Firstin-Human Open-Label Study of LCAR-B38M, a Structurally Differentiated Chimeric Antigen Receptor T (CAR-T) Cell Therapy Targeting B-Cell Maturation Antigen (BCMA), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
Bai-Yan Wang et al.
BLOOD (2019)
Long-term safety and activity of NY-ESO-1 SPEAR T cells after autologous stem cell transplant for myeloma
Edward A. Stadtmauer et al.
BLOOD ADVANCES (2019)
TIGIT immune checkpoint blockade restores CD8(+) T-cell immunity against multiple myeloma
Camille Guillerey et al.
BLOOD (2018)
Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells
Kevin M. Friedman et al.
HUMAN GENE THERAPY (2018)
T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma
Jennifer N. Brudno et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel
David Porter et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1c259 T Cells in Synovial Sarcoma
Sandra P. D'Angelo et al.
CANCER DISCOVERY (2018)
Pre-clinical validation of B cell maturation antigen (BCMA) as a target for T cell immunotherapy of multiple myeloma
De-Xiu Bu et al.
Oncotarget (2018)
Vγ9Vδ2 T Cells in the Bone Marrow of Myeloma Patients: A Paradigm of Microenvironment-Induced Immune Suppression
Barbara Castella et al.
FRONTIERS IN IMMUNOLOGY (2018)
Cytokine release syndrome
Alexander Shimabukuro-Vornhagen et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Tumor Antigen Escape from CAR T-cell Therapy
Robbie G. Majzner et al.
CANCER DISCOVERY (2018)
A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma
Wan-Hong Zhao et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
ALLO-715, an Allogeneic BCMA CAR T Therapy Possessing an Off-Switch for the Treatment of Multiple Myeloma
Cesar Sommer et al.
BLOOD (2018)
JCARH125, Anti-BCMA CAR T-cell Therapy for Relapsed/Refractory Multiple Myeloma: Initial Proof of Concept Results from a Phase 1/2 Multicenter Study (EVOLVE)
Sham Mailankody et al.
BLOOD (2018)
Trends in overall survival and costs of multiple myeloma, 2000-2014
R. Fonseca et al.
LEUKEMIA (2017)
Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells
Juliane Gust et al.
CANCER DISCOVERY (2017)
Restoring Natural Killer Cell immunity against Multiple Myeloma in the era of New Drugs
Gianfranco Pittari et al.
FRONTIERS IN IMMUNOLOGY (2017)
Current Advances in γδ T Cell-Based Tumor Immunotherapy
Elena Lo Presti et al.
FRONTIERS IN IMMUNOLOGY (2017)
Distinctive features of tumor-infiltrating γδ T lymphocytes in human colorectal cancer
S. Meraviglia et al.
ONCOIMMUNOLOGY (2017)
Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis
Bruno Paiva et al.
BLOOD (2016)
Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer
Edmund K. Moon et al.
CLINICAL CANCER RESEARCH (2016)
CD8+tumour-infiltrating lymphocytes in relation to HPV status and clinical outcome in patients with head and neck cancer after postoperative chemoradiotherapy: A multicentre study of the German cancer consortium radiation oncology group (DKTK-ROG)
Panagiotis Balermpas et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma
Syed Abbas Ali et al.
BLOOD (2016)
Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy
Rebecca Gardner et al.
BLOOD (2016)
Development of T-cell tolerance utilizes both cell-autonomous and cooperative presentation of self-antigen
Justin S. A. Perry et al.
IMMUNOLOGICAL REVIEWS (2016)
Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study
Alexander M. Lesokhin et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Toxicity and management in CAR T-cell therapy
Challice L. Bonifant et al.
MOLECULAR THERAPY-ONCOLYTICS (2016)
Autologous genetically engineered NY-ESO-1c259T in HLA-A☆02:01, HLA☆02:05 and HLA☆02:06 positive patients with NY-ESO-1 expressing tumors
Crystal Mackall et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
Antonio Palumbo et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma
Aaron P. Rapoport et al.
NATURE MEDICINE (2015)
The prognostic landscape of genes and infiltrating immune cells across human cancers
Andrew J. Gentles et al.
NATURE MEDICINE (2015)
Adoptive transfer of activated marrow-infiltrating lymphocytes induces measurable antitumor immunity in the bone marrow in multiple myeloma
Kimberly A. Noonan et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Phase I trial of adoptively transferred tumor-infiltrating lymphocyte immunotherapy following concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma
Jiang Li et al.
ONCOIMMUNOLOGY (2015)
Anergic bone marrow Vγ9Vδ2 T cells as early and long-lasting markers of PD-1-targetable microenvironment-induced immune suppression in human myeloma
Barbara Castella et al.
ONCOIMMUNOLOGY (2015)
Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab A Secondary Analysis of the NeoALTTO Trial
Roberto Salgado et al.
JAMA ONCOLOGY (2015)
A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1-Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response
Paul F. Robbins et al.
CLINICAL CANCER RESEARCH (2015)
Current concepts in the diagnosis and management of cytokine release syndrome
Daniel W. Lee et al.
BLOOD (2014)
Neuroblastoma Killing Properties of Vδ2 and Vδ2-Negative γδT Cells Following Expansion by Artificial Antigen-Presenting Cells
Jonathan P. H. Fisher et al.
CLINICAL CANCER RESEARCH (2014)
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Shannon L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Immunological Dysregulation in Multiple Myeloma Microenvironment
Alessandra Romano et al.
BIOMED RESEARCH INTERNATIONAL (2014)
Detailed characterization of tumor infiltrating lymphocytes in two distinct human solid malignancies show phenotypic similarities
Magdalena Kovacsovics-Bankowskil et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2014)
B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma
Robert O. Carpenter et al.
CLINICAL CANCER RESEARCH (2013)
CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia
Renier J. Brentjens et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer
Elena Provasi et al.
NATURE MEDICINE (2012)
Rescued Tolerant CD8 T Cells Are Preprogrammed to Reestablish the Tolerant State
Andrea Schietinger et al.
SCIENCE (2012)
Adoptive immunotherapy for cancer: harnessing the T cell response
Nicholas P. Restifo et al.
NATURE REVIEWS IMMUNOLOGY (2012)
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies
Neha Korde et al.
BLOOD (2011)
Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
Steven A. Rosenberg et al.
CLINICAL CANCER RESEARCH (2011)
From Myeloma Precursor Disease to Multiple Myeloma: New Diagnostic Concepts and Opportunities for Early Intervention
Ola Landgren et al.
CLINICAL CANCER RESEARCH (2011)
Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy
Gavin M. Bendle et al.
NATURE MEDICINE (2010)
Bromohydrin pyrophosphate enhances antibody-dependent cell-mediated cytotoxicity induced by therapeutic antibodies
Julie Gertner-Dardenne et al.
BLOOD (2009)
Clinical and immunological evaluation of zoledronate-activated Vγ9γδ T-cell-based immunotherapy for patients with multiple myeloma
Yu Abe et al.
EXPERIMENTAL HEMATOLOGY (2009)
Prognostic impact of cancer testis antigens expression in advanced stage multiple myeloma patients
Valria C. C. Andrade et al.
BLOOD (2007)
In vitro expansion of gamma delta T cells with anti-myeloma cell activity by Phosphostim and IL-2 in patients with multiple myeloma
Maka Burjanadze et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Professional antigen-presentation function by human γδ T cells
M Brandes et al.
SCIENCE (2005)
Activated marrow-infiltrating lymphocytes effectively target plasma cells and their clonogenic precursors
K Noonan et al.
CANCER RESEARCH (2005)
Potential of human γδ T lymphocytes for immunotherapy of cancer
D Kabelitz et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma:: In vivo persistence, migration, and antitumor effect of transferred T cells
C Yee et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Identification of (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate as a major activator for human γδ T cells in Escherichia coli
M Hintz et al.
FEBS LETTERS (2001)
分享论文
